Markets:

Overview

News

Currencies

International

Treasuries

Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ:RETA)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Reata Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗

August 08, 2022

Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares jumped 132% to $11.12 after jumping around 46% on Friday. The company recently said it expects unaudited comprehensive loss of $1.6...

Via Benzinga

Recap: Reata Pharmaceuticals Q2 Earnings ↗

August 08, 2022

Reata Pharmaceuticals (NASDAQ:RETA) reported its Q2 earnings results on Monday, August 8, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Recap: Reata Pharmaceuticals Q1 Earnings ↗

May 10, 2022

Reata Pharmaceuticals (NASDAQ:RETA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Dow Jumps Over 150 Points; Karuna Therapeutics Shares Spike Higher ↗

August 08, 2022

U.S. stocks traded higher this morning, following the release of strong jobs data on Friday.

Via Benzinga

Why Reata Pharma Shares Are Trading Lower After Q2 Earnings Update? ↗

August 08, 2022

Reata Pharmaceuticals Inc (NASDAQ: RETA) completed a mid-cycle communication meeting with the FDA regarding the marketing application review status for omaveloxolone for Friedreich's ataxia.

Via Benzinga

Why U.S. Stocks Are Trading Higher; Tyson Foods Earnings Miss Views ↗

August 08, 2022

U.S. stocks traded higher this morning, following the release of strong jobs data on Friday.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 08, 2022

Via Benzinga

Reata Pharmaceuticals Earnings Preview ↗

August 05, 2022

Reata Pharmaceuticals (NASDAQ:RETA) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that Reata...

Via Benzinga

Earnings Scheduled For August 8, 2022 ↗

August 08, 2022

Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 07, 2022

Gainers

Via Benzinga

Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday ↗

July 06, 2022

Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday.

Via Benzinga

Reata Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

June 09, 2022

According to data from Benzinga Pro, during Q1, Reata Pharmaceuticals's (NASDAQ:RETA) reported sales totaled $914.00 thousand. Despite a 13.52% increase in earnings, the company posted a loss of $73.84...

Via Benzinga

Where Reata Pharmaceuticals Stands With Analysts ↗

May 27, 2022

Over the past 3 months, 4 analysts have published their opinion on Reata Pharmaceuticals (NASDAQ:RETA) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Pharma Stock Shoots Up As FDA Accepts NDA For Neuromuscular Disorder Drug Under Priority Review ↗

May 26, 2022

Reata Pharmaceuticals (NASDAQ: RETA) announced that the U.S. Food and Drug Administration has accepted New Drug Application (NDA) for its lead drug candidate omaveloxolone for the treatment of patients...

Via Benzinga

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review ↗

May 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For May 10, 2022 ↗

May 10, 2022

Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.

Via Benzinga

Reata Pharmaceuticals Earnings Preview ↗

May 09, 2022

Reata Pharmaceuticals (NASDAQ:RETA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Reata...

Via Benzinga

Reata Stock Enjoys A Two-Day Climb — Why It Could Still Be Facing Everest ↗

April 01, 2022

One analyst says Reata only has a 50% chance in a neurodegenerative disease.

Via Investor's Business Daily

The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study ↗

April 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 28, 2022

Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 38.3% to $1.66 during Monday's regular session. The current volume of 3.5 million shares is 142.9% of TC...

Via Benzinga

35 Stocks Moving In Monday's Mid-Day Session ↗

March 28, 2022

Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) jumped 57.1% to $1.96 following reports regarding potential future investments from AMC CEO, Adam Aron....

Via Benzinga

50 Biggest Movers From Yesterday ↗

March 29, 2022

Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) shares gained 81.3% to close at $2.32 on Monday. Last week, AMC Entertainment Holdings purchased a major stake in...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2022 ↗

March 24, 2022

Upgrades For iRobot Corp (NASDAQ:IRBT), Northland Capital Markets upgraded the previous rating of Market Perform to Outperform. In the fourth quarter, iRobot showed an EPS of $1....

Via Benzinga

Regulus Moving Closer To Potential $25 Million Milestone Payment For Novel Kidney Disease Treatment Licensed To Sanofi ↗

March 18, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Up to 60,000 people in the US with a rare genetic kidney...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates ↗

March 02, 2022

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios...

Via Benzinga

Reata Pharmaceuticals's Return on Invested Capital Insights ↗

March 01, 2022

Benzinga Pro data, Reata Pharmaceuticals (NASDAQ:RETA) reported Q4 sales of $934.00 thousand. Earnings fell to a loss of $85.39 million, resulting in a 18.84% decrease from last...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

February 28, 2022

Gainers IntriCon (NASDAQ:IIN) shares increased by 37.4% to $23.93 during Monday's regular session. The current volume of 1.0 million shares is 3684.0% of IntriCon'...

Via Benzinga

67 Biggest Movers From Yesterday ↗

March 01, 2022

Gainers Mullen Automotive, Inc. (NASDAQ: MULN) climbed 145.6% to close at $1.69 on Monday after the company reported progress on solid-state polymer battery pack...

Via Benzinga

42 Stocks Moving In Monday's Mid-Day Session ↗

February 28, 2022

Gainers Mullen Automotive, Inc. (NASDAQ: MULN) jumped 74.4% to $1.20 after the company reported progress on solid-state polymer battery pack development. Renewable Energy Group...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ:RETA)

Headline News about Reata Pharmaceuticals, Inc. - Class A Common Stock

Starting at $3.75/week.

Subscribe Today